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Abstract
Introduction
Lymphatic filariasis (LF), a neglected tropical disease (NTD) preventable through mass drug
administration (MDA), is one of six diseases deemed possibly eradicable. Previously we
developed one LF elimination scenario, which assumes MDA scale-up to continue in all
countries that have previously undertaken MDA. In contrast, our three previously developed
eradication scenarios assume all LF endemic countries will undertake MDA at an average
(eradication I), fast (eradication II), or instantaneous (eradication III) rate of scale-up. In this
analysis we use a micro-costing model to project the financial and economic costs of each
of these scenarios in order to provide evidence to decision makers about the investment
required to eliminate and eradicate LF.
Methodology/Key findings
Costing was undertaken from a health system perspective, with all results expressed in
2012 US dollars (USD). A discount rate of 3% was applied to calculate the net present value
of future costs. Prospective NTD budgets from LF endemic countries were reviewed to pre-
liminarily determine activities and resources necessary to undertake a program to eliminate
LF at a country level. In consultation with LF program experts, activities and resources were
further reviewed and a refined list of activities and necessary resources, along with their
associated quantities and costs, were determined and grouped into the following activities:
advocacy and communication, capacity strengthening, coordination and strengthening part-
nerships, data management, ongoing surveillance, monitoring and supervision, drug deliv-
ery, and administration. The costs of mapping and undertaking transmission assessment
surveys and the value of donated drugs and volunteer time were also accounted for. Using
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previously developed scenarios and deterministic estimates of MDA duration, the financial
and economic costs of interrupting LF transmission under varying rates of MDA scale-up
were then modelled using a micro-costing approach. The elimination scenario, which
includes countries that previously undertook MDA, is estimated to cost 929 million USD
(95% Credible Interval: 884m-972m). Proceeding to eradication is anticipated to require a
higher financial investment, estimated at 1.24 billion USD (1.17bn-1.30bn) in the eradication
III scenario (immediate scale-up), with eradication II (intensified scale-up) projected at 1.27
billion USD (1.21bn-1.33bn), and eradication I (slow scale-up) estimated at 1.29 billion USD
(1.23bn-1.34bn). The economic costs of the eradication III scenario are estimated at approx-
imately 7.57 billion USD (7.12bn-7.94bn), while the elimination scenario is projected to have
an economic cost of 5.21 billion USD (4.91bn-5.45bn). Countries in the AFRO region will
require the greatest investment to reach elimination or eradication, but also stand to gain the
most in cost savings. Across all scenarios, capacity strengthening and advocacy and com-
munication represent the greatest financial costs, whereas mapping, post-MDA surveil-
lance, and administration comprise the least.
Conclusions/Significance
Though challenging to implement, our results indicate that financial and economic savings
are greatest under the eradication III scenario. Thus, if eradication for LF is the objective,
accelerated scale-up is projected to be the best investment.
Author summary
Lymphatic filariasis (LF) is a neglected tropical disease (NTD) that is targeted for elimina-
tion and is thought to be potentially eradicable through once yearly mass drug administra-
tion (MDA) using drugs that are currently donated to LF endemic countries by the
pharmaceutical companies that manufacture them. MDA has proven to be a cost-effective
and efficient method of disease control, both for LF and other NTDs. Previously, we
developed scale-up scenarios of varying magnitude to reach elimination (elimination of
LF in all countries that have previously undertaken MDA) and eradication (local elimina-
tion of LF in all LF endemic countries) and estimated the number of associated treatments
that would be necessary in each country under each scenario. Here we project the costs—
both financial and economic—of each of these scenarios. We use data from a myriad of
sources to estimate the cost of various activities, and found that training and advocacy
and communication activities comprise the bulk of the costs of the program. Among all
scenarios, elimination requires the least total investment. However, in terms of LF eradi-
cation, faster rates of MDA scale-up are associated with decreased overall costs.
Introduction
Neglected tropical diseases (NTDs) are a heterogeneous group of helminthic, bacterial, viral,
fungal and protozoan infections that cause chronic and debilitating disability [1]. However,
research and development to combat NTDs have notoriously been underfunded [2]. NTDs
persist in areas where access to clean water, hygienic conditions, and health care are limited.
As such, they are most prevalent in low-income countries [1]. Indeed, more than 70% of
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countries with endemic NTDs are classified as low-income or lower middle-income econo-
mies [3]. Infection with an NTD may affect cognitive and physical development and can result
in permanent physical disability. Therefore, NTDs do not just coexist in poverty, they further
propagate the cycle of poverty by hindering economic potential [4, 5].
Lymphatic filariasis (LF), an NTD, can result in irreversible disability, most often mani-
fested as elephantiasis, lymphedema, and hydrocele [6]. With more than a billion people at-
risk and 120 million people thought to be infected across 73 countries [7], LF is estimated to
account for 2.74 million disability-adjusted life years (DALYs) (1.73m-4.00m) [8]. When
incorporating the mild and moderate depression associated with LF-related disability, the
health burden due to LF may be upwards of 5 million DALYs [9].
However, while LF can result in profound morbidity, it is inefficiently transmitted, with an
estimated 15,500 infective mosquito bites thought necessary to generate one transmittable
infection [10]. LF is also preventable through once yearly treatment with antifilarials distrib-
uted through mass drug administration (MDA) [6]. This, coupled with the fact that LF does
not have a significant animal reservoir, led the International Task Force on Disease Elimination
to classify LF as a potentially eradicable disease [11, 12]. In response, the World Health Organi-
zation (WHO) began the Global Program to Eliminate LF (GPELF), which aims for the global
elimination of LF by 2020 [6]. In the fifteen years since the inception of the GPELF more than
five billion antifilarial treatments have been distributed in 58 LF-endemic countries [13].
Successfully eradicating a disease has innumerable long-term health benefits, and is also a
classic example of a global public good [14–16]. Eradicating an NTD, like LF, has additional
societal benefits, including improvements towards equity, fairness, and social justice [17].
However, disease elimination and eradication initiatives require substantial social and political
commitments, as well as significant financial and economic investments. Given the increas-
ingly intense competition for global health resources, the decision on where to invest funds
needs to be based upon solid evidence [18]. In order to provide evidence to decision makers
about the investment required to eliminate and eradicate LF, we used a micro-costing
approach to analyze the financial and economic costs of interrupting LF transmission in all
endemic countries under varying levels of MDA intensity, as well as the subsequent costs of
conducting post-MDA surveillance.
Methods
Scenarios
We previously developed scenarios to reach elimination (elimination of LF transmission in
countries that have previously undertaken MDA) and eradication (elimination of LF transmis-
sion in all endemic countries) of LF, taking into account previous progress made under the
GPELF, pre-intervention prevalence levels, and possible delays in program implementation.
The elimination scenario maintains the current geographic expansion and rate of MDA scale-
up as seen under the GPELF, and thus serves as the comparator scenario. The eradication sce-
narios were developed to assess the impact of expanding MDA to all endemic countries at an
average rate of MDA scale-up (eradication I), intensifying efforts against LF (eradication II),
and treating all endemic populations immediately (eradication III). Key components inherent
in each scenario are outlined in S1 Table and a full explanation of all the scenario can be found
in Kastner et al [19].
Timeframe and number of treatments required
To determine the duration of MDA required for the different drug regimens, vector species,
and pre-intervention prevalence levels, we used EpiFil, a deterministic model of LF
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transmission [20]. The amount of time and number of treatments required to reach the end-
points in each scenario are detailed in Kastner et al. [19]. Briefly, we considered the number of
MDA rounds that each country had previously achieved a programmatic coverage of at least
65% (the minimum coverage necessary to be considered effective) between 1999 and 2012.
Using Epifil, we then determined the expected number of rounds of annual MDA treatments
at the level calculated to result in elimination in 97.5% of simulations. Assuming the number
of MDA rounds required to interrupt transmission as a deterministic value, we next subtracted
the number of rounds of MDA required to reach local elimination from the number of previ-
ously effective years. Assuming once-annual MDA (aside from areas co-endemic with hyper
Loaisis; see: Assumptions about L. loa endemic areas), we then determined the number of future
treatments needed for each country under each scenario, accounting for the number of people
at-risk, country-specific growth rates, duration of MDA necessary, historical rates of scale-up,
and previous progress towards local elimination. By assuming that the populations at-risk for
LF increase exponentially with population growth rates, scenarios with longer durations were
also assumed to require more treatments (see S1 Table).
Approach used for costing
To assess how much governments and donors would need to invest in order to implement the
GPELF strategy to reach the elimination and eradication of LF, we adopted a micro-costing,
bottom-up approach from the perspective of the health system of each LF endemic country. In
contrast to gross-costing, which assesses average level costs from the top down, micro-costing
may improve the accuracy of results by capturing resources and costs at the unit level [21].
The costs associated with each scenario have been assumed to begin in the year 2014 and
run until the final post-MDA transmission assessment survey (TAS) has been completed in
each country under consideration. All results are listed in 2012 US dollars (USD) and future
costs were discounted at 3%. One-way sensitivity on discount rates, variability rates, and prob-
abilistic sensitivity analyses for all costing and quantity parameters were also explored. Two-
way sensitivity analyses were also employed to explore the level of interdependence between
key parameters and activities.
Data
Line items from USAID’s NTDMaster Plan Costing Tool in the African Region for Benin, Cam-
eroon, Democratic Republic of Congo, Eritrea, Guinea, Madagascar, Niger, Senegal, and Sierra
Leone ranging from January 2011 to April 2012 were reviewed to preliminarily determine
essential activities and associated resources necessary for a country to successfully undertake a
program to eliminate lymphatic filariasis (PELF). Subsequently, in consultation with key LF
implementers from the PELF in Uganda, which has successfully been carrying out the GPELF
MDA strategy since 2002 [13], all activities and resources were further reviewed and a refined
list of core activities, necessary personnel, components, and resources, along with their associ-
ated costs, were ascertained [22].
Retail prices from established vendors were used for tradable goods, including laboratory
supplies and capital items. The WHO CHOICE database was used for unit costs which were
unable to be determined elsewhere. While the percentage of time needed for LF personnel was
informed by the Ugandan program, the country-specific salary estimates were taken from the
WHO CHOICE database for the NTD director (assumed to be 0.2 full time equivalent (FTE),
LF program manager (1.0 FTE), administrative assistant (0.5 FTE), finance officer (0.3 FTE),
data manager (0.3 FTE), and supplies manager (0.5 FTE). As the African Program for
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Onchocercaisis Control (APOC) uses a strategy similar to that employed by the GPELF [23],
line items in our study were validated against similar line items found in APOC approved
budgets.
Activities considered
We took into account the cost of advocacy and communication; capacity strengthening; coor-
dination and strengthening partnerships; mapping; data management; administration; ongo-
ing surveillance; monitoring, evaluation, and supervision (M&E); drug delivery; and post-
MDA transmission assessment surveys (TAS). As described below, the costs of increased sur-
veillance in areas with meso L. loa prevalence, as well as the added cost of biannual MDA in
hyper loaisis areas were also accounted for.
Advocacy and communication was assumed to include the development and distribution
of educational messages, as well as community meetings and sensitization activities with dis-
trict and community leaders, sub-county and parish supervisors, and community drug distrib-
utors (CDDs). Capacity strengthening comprised trainings on MDA procedures for national
trainers, district trainer of trainers, sub-county and parish supervisors, community leaders,
CDDs and teachers. Trainings for monitoring sentinel and spot check sites as well as trainings
for M&E officers were also considered under capacity strengthening. Conference attendance
and international exchanges, cross-border meetings for regional strategies towards controlling
NTDs, NTD secretariat meetings, and technical committee meetings were assumed under
coordination and strengthening partnerships. Data management included all activities
involved with the acquisition and distribution of MDA data, including cleaning, entering, and
analyzing. The maintenance of sentinel sites—including equipment for administering microfi-
laria (mf) surveys and internal quality control tests—as well as the administration of sentinel
and control site impact assessment surveys, associated data collection, and survey feedback
meetings were grouped under ongoing surveillance. M&E included the supervision of MDA
activities, monitoring for severe adverse events (SAEs), and regular feedback meetings at the
district and national level. Drug delivery involved drug transport from the central stores to dis-
trict stores and then onward to parish supervisors. Supplies to CDDs, including t-shirts and
stationery, were also accounted for under drug delivery. Administration included overhead
costs, the maintenance of office space, salaries to LF staff, and the procurement of necessary
equipment.
Mapping and TAS were assumed to include a preliminary visit, immunochromatographic
card test (ICT) testing, data collection, and feedback meetings. The cost of mapping was
included for any country that, as of 2012, had not yet completed mapping nor started MDA. In
order to determine the costs of post-MDA surveillance on a global level, all TAS have been
assumed to be school-based. Moreover, TAS have been assumed to occur in each district (see
Determination of resource quantities for assumptions about district size) after the final esti-
mated round of MDA (as determined through earlier modeling exercises) and twice thereafter
at three year intervals. The number of TAS conducted has thus been assumed to vary by the
number of districts achieving the specified number of MDA rounds, though the quantities of
resources required for each individual TAS was assumed to remain constant.
Assumptions about Loa loa endemic areas
Previous studies indicate that individuals harboring more than 30,000 L. loa microfilaria per
milliliter of blood are put at unacceptably high risk of developing severe adverse events (SAEs)
if administered ivermectin or diethylcarbamazine citrate (DEC) [24–26]. As L. loa prevalence
within a community has been shown to have a close correlation with individual L. loa mf
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density, provisional GPELF guidelines recommend communities endemic with LF that also
have a L. loa prevalence greater than 40% be treated with bi-annual MDA using albendazole
monotherapy coupled with vector control [27].
Mapping studies to determine areas of co-endemicity between LF and L. loa, however, are
not yet complete. While we recognize that not all populations at-risk for L. loa are also at-risk
for LF, for the purposes of this study, we make the assumption that the percentage of mapped
areas from RAPLOA studies that were found to have 20–39.9% (meso) or>40% (hyper) L. loa
prevalence corresponds directly to the percentage of the population in these countries also at
risk for LF [13, 28]. In assessing the costs for undertaking the LF program in these areas, we
further assume the cost of vector control to be covered by other initiatives. In line with the pro-
visional recommendations, we assume that the population living in hyper-endemic areas will
receive bi-annual albendazole through MDA. Financially, this is assumed to double the costs
of data management and drug delivery in these areas. For populations in meso-endemic
regions of L. loa, once yearly albendazole and ivermectin is still presumed. In areas of both
hyper and meso L. loa, the costs associated with monitoring for SAEs are assumed to increase
two-fold.
Determination of resource quantities
In line with the approach for assessing necessary activities, quantities and duration of use for
each required component were established through consultation with key members from the
Ugandan PELF team. Aside from program activities with inherently fixed costs—such as the
creation and dissemination of health messages, coordination and strengthening of partner-
ships, and administrative costs—budgeted line items were assumed to vary linearly by the size
of the population to be treated (see below: Timeframe and number of treatments required). In
the baseline analysis, we have assumed that the number of resources required to carry out the
PELF for a certain population in Uganda is relatively similar to the number of resources
required to carry out the program for a population of similar size in other LF endemic coun-
tries. As MDA in Uganda is implemented at a community level, the amount of resources and
duration of activities required to successfully complete the PELF in Uganda are generally orga-
nized by district, sub-county, and village units. In order to standardize the at-risk population
falling into the different administrative levels (districts, sub-counties, and villages) across all
LF endemic countries, the average number of people at-risk for LF in each district, sub-county,
and village were determined for Uganda and then assumed for all LF-endemic countries.
Determination of distances and transport costs
We assumed the costs to transport both people and supplies within each LF endemic country
to vary by a function of distance traveled and country-specific petrol prices. Using NTD
national control program plans from 22 LF endemic countries, we estimated the driving dis-
tances between each country’s capital city and each of their districts. We then averaged these
results and related them to the surface area of the respective country. The resulting average for
the 22 countries was then used to relate the surface area of the other LF endemic countries for
which NTD national control program plans were unavailable to intra-country distances. Dis-
tance estimates were then paired against the median price of 1 liter of petrol in each LF
endemic country, as reported by Numero in order to estimate transport costs.
Determination of financial costs
In 2013, the median GDP per capita among LF endemic countries was estimated at 1,245.51
USD, ranging from 226.46 USD in Malawi to 25,140.29 USD in Brunei [29]. Given the highly
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variable economic conditions across LF endemic countries and lack of expenditure data avail-
able for this analysis, we proceeded to estimate unit costs for all local, non-tradable goods and
services for each LF endemic country by adjusting detailed expenditure budgets from the LF
elimination program in Uganda, a country with a GDP per capita estimated at 571.96 USD
[29], by country-specific comparative price levels (i.e., purchasing power parity (PPP) adjusted
exchange rates) [30]. Tradable goods were assumed to already be at market value and were
thus left unadjusted. Table 1 provides a list of the primary activities considered in calculating
the financial costs, as well as the average cost per district in the base case.
Determination of economic costs
Economic costs, which were assumed to encompass financial costs as well as the value of vol-
unteer time and donated pharmaceuticals, were also estimated in order to have a more com-
prehensive understanding of the projected investment needed to eliminate and eradicate LF
[31]. A schematic of the algorithm used for calculating the financial and economic costs is
depicted in Fig 1.
Value of donated pharmaceuticals. The opportunity costs of the donated drugs used in
the GPELF were accounted for by valuing each 400 mg tablet of albendazole at 0.19 USD, 50
mg tablet of DEC at 0.0025 USD, and 3 mg tablet of ivermectin at 0.50 USD, which were the
suggested manufacturer prices prior to being donated [32–34]. An additional economic cost of
0.0018 USD was assumed to the value of each tablet for insurance and shipping costs, which
also are currently absorbed by the drug manufacturers [34]. While the WHO specifies each
treatment to include either 6 mg DEC/kg of body weight or 150 μg ivermectin/kg of body
weight plus 400 mg ALB, for the purposes of this global level exercise, we assume all annual
MDA treatments to be comprised of one tablet of ALB with either three tablets of ivermectin
or seven tablets of DEC.
Value of volunteer time. The value of donated time was evaluated by correlating the time
CDDs were presumed to volunteer under each scenario with country-specific or, when neces-
sary, region-specific daily per worker agriculture wage estimates taken from the World Bank’s
World Development Indicators Online, inflated to 2012 [35]. Two CDDs were assumed to be
sufficient to dispense MDA in each village [36]. Drawing from the results of previous time
studies, CDDs were assumed to volunteer 5.5 days on mobilization and sensitization, 4.6 days
conducting pre-MDA census activities, and 17.8 days on drug distribution [37].
Uncertainty analysis
To account for the uncertainty in our model parameters, and to examine the affect of this
uncertainty on the outcome and conclusions of our study, we conducted a series of uncertainty
analyses. For the primary analysis, we conducted a probabilistic sensitivity analysis (PSA)
involving all financial unit costs and quantities assuming 10% uncertainty and gamma distri-
butions for all parameters in order to avoid negative values [38]. As the covariance between
parameters was unknown, we further assumed all parameters to be independent. For all sce-
narios, we ran the model for 500 iterations for every year in every country. The model outputs
thus provide a distribution of cost results, reported as median estimates and associated 95%
credible intervals. Additional details involved in conducting the PSA can be found in the S1
File. Additional sensitivity analyses, including the impact of assuming 30% uncertainty of all
input parameters, as well as a series of two-way sensitivity analyses to assess possible correla-
tion between parameters can also be found in the supplementary material (S1 File, S2 and S3
Figs, S3, S4 and S5 Tables).
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Table 1. Average costs per district, base case.
Activity Average costs per district (standard
deviation)
Frequency (implementation phase*)
Advocacy and communication
Community meetings $8,946.96 ($686.11) Annually
Social mobilization—District leaders $469.95 ($18.30) Annually
Social mobilization—Sub-county supervisors $256.39 ($20.12) Annually
Social mobilization—Parish supervisors, CDDs,
community leaders
$8,821.35 ($753.30) Annually
Workshop for creating messages $5.61 ($0.22) Once every 5 years
Dissemination of health messages $916.44 ($54.62) Once every 5 years for printed messages; Annually for
verbal messages
Capacity strengthening
Training national trainers, MDA and M&E $14.31 ($0.54) Annually
Training of district trainers of trainers, MDA and M&E $800.35 ($31.22) Annually
Training of sub-county supervisors, MDA and M&E $754.87 ($50.60) Annually
Training of parish supervisors and community leaders,
MDA and M&E
$20,991.65 ($2,141.29) Annually
Training of CDDs $15,848.40 ($1,655.98) Annually
Training of teachers $4,748.92 ($520.45) Annually
Training for monitoring sentinel and spot check sites $690.36 ($49.50) Annually
Training M&E officers $1,310.23 ($56.96) Annually
Coordination and strengthening partnerships
Conference attendance and international exchanges $83.04 ($1.16) Annually
Attend cross-border meetings for LF and NTDs $141.62 ($1.69) Annually
NTD secretariat meeting $81.81 ($3.35) Annually
Technical committee of NTDs $38.28 ($1.71) Annually
Data management
Cleaning, entering, analyzing data $119.54 ($6.96) Annually
Transfer of data from field to head office $704.69 ($93.39) Annually
Ongoing surveillance
Maintain sentinel sites $1,616.73 ($8.80) Annually
Site survey—data collection $3,000.23 ($94.92) Annually
Site survey—feedback meetings $1,589.09 ($36.39) Annually
Transmission assessment surveys—preliminary visit $1,165.08 ($40.04) Annually
Transmission assessment surveys—data collection $2,849.99 ($55.82) Annually
Transmission assessment surveys—feedback
meeting
$1,438.37 ($35.32) Annually
Monitoring, evaluation, and supervision
Supervision of MDA $18,216.02 ($485.16) Annually
Feedback meetings at district level $884.54 ($37.36) Annually
Feedback meetings at national level $19.34($0.53) Annually
Drug delivery
Supplies for CDDs $3,924.54 ($485.62) Annually
Drug transport $3,078.94 ($180.55) Annually
Administration
Overhead costs $377.36 Annually
Salaries, LF staff $950.19 ($51.04) Annually
Procurement of necessary equipment and software $61.63 ($2.23) Annually
*In the base case, the implementation period runs from 2014–2023
https://doi.org/10.1371/journal.pntd.0005934.t001
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Results
The total financial investment to implement the elimination scenario is projected at 929 mil-
lion USD (891m-965m). To expand the campaign to all endemic countries at an average rate
of scale-up (eradication I scenario) would require 1.29 billion USD (1.24bn-1.34bn), an
increase of about 360 million USD (346m-374m) over the elimination scenario (Fig 2). The
decrease in scenario duration inherent in the eradication II scenario (intensified scale-up)
comes with decreased costs, estimated at 1.27 billion USD (1.22bn-1.32bn), while instan-
taneously scaling up MDA to all LF endemic countries is projected to require an investment of
1.24 billion USD (1.18bn-1.28bn). The AFRO region accounts for 62–68% of the financial
costs, with Southeast Asia requiring between 22–30% of the projected investment (Table 2).
Providing MDA to the entire at-risk population immediately, as assumed under the eradi-
cation III scenario, requires a significant initial investment, but within 10 years’ time, the
annual cost of implementing the scenario becomes less than the alternatives (Fig 3). The sharp
increase in financial costs four years from the start of the eradication III scenario corresponds
Fig 1. Financial and economic costing algorithm.
https://doi.org/10.1371/journal.pntd.0005934.g001
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Fig 2. Incremental financial costs (elimination scenario as comparator).
https://doi.org/10.1371/journal.pntd.0005934.g002
Table 2. Total financial costs by region (in millions USD).
Elimination (comparator) Eradication I Eradication II Eradication III
AFRO $ 574m
($547m-$600m)
$ 878m
($841m-$915m)
$ 871m
($833m-$907m)
$ 840m
($802m-$877)
SEAR $ 278m
($266m-$289m)
$ 278m
($266m-$289m)
$ 279m
($267m-$292m)
$ 279m
($266m-$292m)
WPR $ 56m
($55m-$58m)
$ 67m
($65m-$68m)
$ 58m
($56m-$59m)
$ 54m
($53m-$56m)
AMR $ 21m
($20m-$22m)
$ 21m
($20m-$22m)
$ 19m
($18m-$20m)
$ 18m
($18m-$19m)
EMR $0.44m
($0.43m-$0.45m)
$ 46m
($44m-$48m)
$ 47m
($44m-$49m)
$ 43m
($40m-$46m)
Total Financial Cost $ 929m
($891m-$965m)
$ 1,289m
(1,239m-1,337m)
$ 1,273m
(1,223m-1,322m)
$ 1,235m
(1,183m-1,284m)
Total Economic Cost $ 5,187m
($4,907m–$5,450m)
$ 7,915m
($7,498m–$8,300m)
$ 7,975m
($7,547m–$8,366m)
$ 7,532m
($7,117m–$7,937m)
https://doi.org/10.1371/journal.pntd.0005934.t002
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to the start of MDA to all at-risk populations in countries that were previously delayed due to
mapping.
The average unit financial cost for undertaking each of the scenarios ranges from 0.27 USD
in the elimination scenario to 0.31 USD in both the eradication II and III scenarios. However,
as the scenarios progress, the unit costs increase substantially. This is due to the fact that the
number of people to be treated (the denominator of the estimate) decreases, though the cost
associated with some of the core activities—including coordination and strengthening part-
nerships, administration, and data management—are assumed to remain relatively constant.
As an example of this, Fig 4 depicts the unit financial costs seen under eradication I, which, by
2050, extend to more than 1,700 USD per person treated.
Capacity strengthening proves to be the most costly activity, representing between 53–55%
of the overall financial costs, while advocacy and communication (22–24%); ongoing surveil-
lance (6%); monitoring, evaluation, and supervision (8%); and drug delivery (9%) account for
most of the remaining costs (Table 3).
Our assessment of the financial costs of treating a population of 1 million at-risk for LF
with and without L. loa coendemicity in the Democratic Republic of Congo indicates that
areas of meso L. loa are anticipated to only result in an increase in monitoring and evaluation,
thereby having little effect on the overall costs. In comparison to a population of comparable
size without L. loa, hyper L. loa endemicity is associated with an increase of approximately
15% in the overall costs of the program due to the increase in data management, drug delivery,
and monitoring and evaluation activities.
When the economic costs are considered, the costs of all scenarios are substantially higher
(5.2 billion USD for the elimination scenario). Extending the coverage to all endemic countries
is estimated to require around 7.9 billion USD (7.5bn–8.0bn), or 45% more than under the
elimination scenario (Table 2). Depending on the scenario, between 48–53% of the economic
costs are due to the value of the donated drugs (Fig 5).
Fig 3. Financial costs by year, discounted at 3%.
https://doi.org/10.1371/journal.pntd.0005934.g003
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Discussion
This study used a micro-costing approach to provide estimates on the financial and economic
investments required to eliminate and eradicate lymphatic filariasis. Across the eradication
Fig 4. Financial cost per person treated, eradication I.
https://doi.org/10.1371/journal.pntd.0005934.g004
Table 3. Percentage of financial costs by activity.
Elimination Erad I Erad II Erad III
Advocacy and communication 24% 22% 23% 24%
Capacity strengthening 53% 55% 55% 53%
Coordination and strengthening partnerships <1% <1% <1% <1%
Data management <1% 1% 1% 1%
Ongoing surveillance 6% 6% 6% 6%
Monitoring, evaluation, and supervision 8% 8% 8% 8%
Drug delivery 9% 9% 9% 9%
Post MDA Surveillance <1% <1% <1% <1%
Administration <1% <1% <1% <1%
Mapping - <1% <1% <1%
https://doi.org/10.1371/journal.pntd.0005934.t003
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scenarios, faster rates of MDA scale-up are associated with decreased costs (1.2 billion USD in
the eradication III scenario versus 1.3 billion USD in the eradication I scenario). The projected
economic costs of eradication range from 7.5 billion to 8.0 billion USD, about half of which is
due to the value of the donated drugs. These results serve to further highlight both the impor-
tance of higher rates of MDA scale-up as well as the crucial partnership between the GPELF
and the drug donation programs. These projections may also be important in order to con-
vince pharmaceutical companies to continue donating the drugs necessary to eliminate LF.
While the cost to eliminate LF is less than that to eradicate, it must be recognized that deciding
to pursue elimination rather than eradication signifies the continuation of LF-related costs
indefinitely, and comes at a health burden to populations that remain untreated.
With a dearth of evidence on the costs of implementing morbidity management programs
[39], and given that the aim of our study was to assess the costs of interrupting transmission of
the causative agent of LF, we did not include the costs of morbidity management in our
Fig 5. Economic costs by component, discounted at 3%.
https://doi.org/10.1371/journal.pntd.0005934.g005
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estimates. Had morbidity management been included in the scenarios, the overall costs would
have certainly increased, though presumably with reduced times to eradication associated with
reduced morbidity management costs.
Our cost estimates for reaching LF elimination and eradication inherently assume that the
GPELF strategy, if carried out sufficiently, will lead to the interruption of LF transmission in
all areas. In our analysis we have also assumed that accelerating the rate of MDA scale-up will
result in decreased marginal costs (the cost of one additional treatment) by assuming there to
be spare capacity among fixed costs (cars, equipment, etc.). However, in some areas, additional
capital may be required and, therefore, marginal costs would increase. In such a case, accelerat-
ing eradication might not be the most cost-saving option in the short term.
Additionally, our analysis does not take into account the cost for certifying elimination on a
country level nor the activities involved in globally assessing whether eradication has been
achieved. As currently experienced by the Global Polio Eradication Initiative, the costs for
finding and ascertaining the last cases to reach eradication are substantial [40, 41]. While our
analysis does not consider the costs associated with finding the last cases of LF infection, the
unit costs for the final populations treated in the eradication I scenario are orders of magnitude
higher than the average unit costs—beyond 1,700 USD per person treated. This is due to fewer
people to be treated (the denominator of the calculation) rather than higher overall costs of
running the program. It has previously been recognized that when the cost of disease eradica-
tion comes within reach, the unit costs associated with prevention become decreasingly attrac-
tive. However, at that point, it is crucial not to lose momentum, nor investment, otherwise
there is great risk of failure [42, 43]. Developing realistic cost projections from the start of the
program could help mitigate the risk of donor fatigue towards the endgame of disease eradica-
tion. Further, when disease eradication is within reach, shifting the focus from unit costs per
person treated to the costs per case averted may also help to sustain global commitments [44].
Our analysis found a 15% increase in financial costs to treat an area of hyper L. loa
endemicity in the DRC. This estimate does not take into account increases in advocacy and
communication in these areas, which may be necessary to achieve the targeted levels of cover-
age. Further, the costs for medical transport and additional medications that might be needed
to treat patients suffering from severe adverse events have not been incorporated in this analy-
sis. Costing studies for such post-MDA response activities have not previously been carried
out, though such costs are likely to vary by the incidence of SAEs, the geographic location, and
the intensity of response required. If substantial and significant response is required in many
areas, implementing the eradication scenarios would certainly result in higher costs than pro-
jected in this baseline study.
A number of methodological uncertainties in our study must be mentioned. Country-spe-
cific cost data was mostly unavailable and, consequently, was largely imputed from Ugandan
data. By extrapolating cost data across countries and regions, we inherently made the assump-
tion that each LF endemic country implements the GPELF strategy as in Uganda (for example,
using volunteer CDDs, similar amount of trainings, etc.). Moreover, we assumed that the
number of resources required to carry out the PELF for a certain population in Uganda
remains relatively constant (varying by +/-10%) both across time and across countries. As
described above, the variation assumed in our model was included probabilistically in both
unit costs and quantities.
We chose to have modest uncertainty assumptions, assuming a variation of 10% probabilis-
tically for both costs and quantity estimates. Though 10% variation has a large impact on the
individual unit costs, the impact on total costs was less than expected. As such, we chose to
increase the variability to 30% during additional uncertainty analyses. However, this resulted
in only a modest increase in the uncertainty intervals (see S3 Table and S1 Fig). It is, therefore,
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likely that the narrow uncertainty intervals found in this analysis are the result of assumptions
made during earlier analyses to estimate the number of annual rounds of treatment required
to interrupt LF transmission. Namely, we assumed the required number of annual rounds of
treatments to be fixed at the upper bound of our model-based projections in order to provide
as conservative an estimate as we could. Varying the estimated number of treatments across
their credible interval may have instead provided a more complete picture.
Additionally, our MDA round estimates are considerably longer than the 4–6 years cur-
rently specified by the GPELF, instead ranging from 6 rounds of MDA in areas where Anophe-
les spp are the primary vector, treatment is through DEC+ALB, and the baseline MF
prevalence is 5–10%, to 15 rounds in areas where Culex spp are the primary vector, IVM+ALB
is the treatment provided and the baseline mf prevalence is 15–20% [19, 45]. These extended
MDA durations have a number of implications, but most relevant in terms of costing is that
both the financial and economic estimates are likely to be much more conservative than esti-
mates developed using an assumed 4–6 years of MDA, since the overall costs are heavily
dependent on the duration of the program. Our approach, therefore, resulted in conservative
estimates at the cost of capturing more realistic uncertainty intervals. In our baseline analysis
we chose to make rather crude assumptions of independence between inputs as well as
assumptions of the uncertainty and distributions of the model inputs. For the purposes of
assessing the relative costs of scaling up MDA at different rates we felt that this was sufficient
in order to avoid introducing increased complexity, and consequently, further uncertainty in
our model.
Ideally, LF-specific expenditure data would have been collected in all 72 LF-endemic coun-
tries. Having such data would have also allowed for an important assessment on the variance
of costs from the beginning stages of implementation towards the ‘end game’ of reaching sur-
veillance. However, 14 of these endemic countries have never carried out MDA for LF [13].
Moreover, undertaking a study that accurately collected such data would potentially begin to
rival the time and cost of running the PELF programs in many of the countries to begin with.
Further, a recent study by Brady et al. found no significant difference between grant budgets
and actual expenditures when analyzing costs of Transmission Assessment Surveys [46]. Thus,
despite the large number of assumptions inherent in our approach, our costing model allowed
for the development of comparable cost estimates on a country, regional, and global level.
We conducted a probabilistic sensitivity analysis in order to overcome some of the limita-
tions inherent in our costing parameters. In order to provide more robust estimates on the
costs of achieving elimination and eradication, costing studies in areas with the highest burden
of LF could be undertaken in order to reduce the level of uncertainty in costs. While improved
cost data could be used to inform policy and improve planning, the cost of acquiring addi-
tional data should be weighed against the value of such data [47]. An additional use for the
results found in our economic analyses, therefore, could be to assess the value of additional
investments for LF, including the collection of expenditure data, as well as investments in diag-
nostics, drugs, and surveillance tools to help advance LF eradication.
Our findings on the costs to eliminate and eradicate LF represent very achievable invest-
ments. Our cost estimates would have likely been even lower, though, if we assumed some
level of integration or cost-sharing between other disease initiatives. Many countries have, in
fact, integrated similar activities across vertical programs, including onchocerciasis, trachoma,
and schistosomiasis, and others have paired drug delivery for MDA with other community dis-
tribution campaigns, including insecticide treated nets (ITNs) for malaria and ongoing vaccine
programs. In so doing, the overall costs per program, indeed, generally decreased and effi-
ciency reportedly improved [2, 48–51]. However, it is important to note that, historically,
other disease elimination programs that have proven to be successful have generally proceed
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as vertical programs [52]. Additionally, given the cost involved with each round of MDA, it
could be cost saving to undertake TAS sooner in order to assess whether the interruption of
transmission had been achieved. However, this approach could prove to be a difficult balance,
since prematurely stopping MDA could result in resurgence of infection [53], ultimately lead-
ing to an increase in the cost of reaching eradication.
We further did not include the cost of vector control in this costing study, assuming instead
the cost to be covered by other disease control programs (for example: malaria or dengue con-
trol). While vector control is not a core strategy of the GPELF in non l. loa endemic areas, pre-
vious studies have indicated that including vector control could decrease the number of MDA
rounds needed to interrupt transmission, thereby reducing the overall duration of the program
[54], and potentially also the cost.
A comparison of our costs against other costs is important for validation, though challeng-
ing due to differing methodologies. Though not inclusive of overhead costs, a study from two
states in Nigeria found the cost associated with conducting MDA for the prevention of LF to
be between 0.02 USD and 0.12 USD per treatment delivered [55]. A multi-country costing
study conducted by Goldman et. al found unit financial costs to range from 0.06 USD in Bur-
kina Faso to 2.23 USD in Haiti [34]. A separate study in Haiti reported the cost per person
treated to be 1.44 USD [56]. Thus, in comparison to other MDA costing studies, our average
unit financial cost estimates are well within the range of previously reported studies.
Knowing the global costs of the program will help decision makers assess the feasibility and
rationale of investing in LF eradication, while simultaneously helping to facilitate planning
and the development of strategies and policies. However, successfully eradicating LF depends
on more than the monetary investment. Political will, continued community ownership, and
the feasibility of the campaign all need to be taken into account [57]. However, if successful,
disease eradication not only results in innumerable long-term health benefits, but also savings
to the health system, gains in productivity, and improvements in social justice [17, 58]. The
decision of whether disease eradication should be pursued, therefore, needs to be approached
with a comprehensive understanding of the many complex issues at play.
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